<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730804</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1830-HV-108</org_study_id>
    <secondary_id>2020-001081-11</secondary_id>
    <nct_id>NCT04730804</nct_id>
  </id_info>
  <brief_title>A Study of ALXN1830 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of Subcutaneous ALXN1830 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the effects of single and multiple doses of ALXN1830 in healthy adult&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study in healthy adult participants. The study will consist of 2 single&#xD;
      ascending dose (Cohorts 1 and 2) and 4 multiple ascending dose cohorts (Cohorts 3 to 6).&#xD;
      Participants will be randomly assigned to each of the 6 cohorts to receive either single or&#xD;
      multiple doses of ALXN1830 subcutaneous (SC) or single or multiple doses of placebo SC.&#xD;
      Cohort 6 will enroll only healthy participants of Japanese descent who will be dosed&#xD;
      according to the highest tolerated dose (HTD) established in the non-Japanese cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Program is undergoing further evaluation&#xD;
  </why_stopped>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up (up to 63 [+/- 1] days after last study drug administration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration-time Curve From Time 0 (Dosing) To Time Infinity (AUC0-inf) Of Serum ALXN1830 For Single And Multiple Doses</measure>
    <time_frame>Up to 141 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Immunoglobulin G (IgG) For Single And Multiple Doses Of ALXN1830</measure>
    <time_frame>Up to 141 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Incidences Of Treatment-emergent Adverse Events Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830</measure>
    <time_frame>Day 1 (postdose) through follow-up (up to 63 [+/- 1] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of AUC0-inf Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830</measure>
    <time_frame>Up to 141 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of IgG Levels Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830</measure>
    <time_frame>Up to 141 days postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ALXN1830 Single Dose 1/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single SC dose of ALXN1830 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ALXN1830 Single Dose 2/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single SC dose of ALXN1830 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: ALXN1830 Multiple Dose 1/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple SC doses of ALXN1830 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: ALXN1830 Multiple Dose 2/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple SC doses of ALXN1830 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: ALXN1830 Multiple Dose 3/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple SC doses of ALXN1830 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: ALXN1830 /Placebo in Japanese Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive multiple SC doses of ALXN1830 (HTD) or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1830</intervention_name>
    <description>ALXN1830 will be administered as SC infusion(s).</description>
    <arm_group_label>Cohort 1: ALXN1830 Single Dose 1/Placebo</arm_group_label>
    <arm_group_label>Cohort 2: ALXN1830 Single Dose 2/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: ALXN1830 Multiple Dose 1/Placebo</arm_group_label>
    <arm_group_label>Cohort 4: ALXN1830 Multiple Dose 2/Placebo</arm_group_label>
    <arm_group_label>Cohort 5: ALXN1830 Multiple Dose 3/Placebo</arm_group_label>
    <arm_group_label>Cohort 6: ALXN1830 /Placebo in Japanese Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as SC infusion(s).</description>
    <arm_group_label>Cohort 1: ALXN1830 Single Dose 1/Placebo</arm_group_label>
    <arm_group_label>Cohort 2: ALXN1830 Single Dose 2/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: ALXN1830 Multiple Dose 1/Placebo</arm_group_label>
    <arm_group_label>Cohort 4: ALXN1830 Multiple Dose 2/Placebo</arm_group_label>
    <arm_group_label>Cohort 5: ALXN1830 Multiple Dose 3/Placebo</arm_group_label>
    <arm_group_label>Cohort 6: ALXN1830 /Placebo in Japanese Population</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Satisfactory medical assessment.&#xD;
&#xD;
          -  Participants must have had vaccination against pneumococcus (Pneumovax 23 [PPSV23]) at&#xD;
             least 28 days, and maximally 4 years prior to Day 1.&#xD;
&#xD;
          -  Participants must have had seasonal influenza vaccination for the current season at&#xD;
             least 28 days prior to Day 1.&#xD;
&#xD;
          -  Body weight within 60 to 90 kilograms (kg), inclusive, and body mass index within 18&#xD;
             to 30 kg/meter squared, inclusive.&#xD;
&#xD;
          -  Must be willing to follow protocol-specified contraception guidance during the study&#xD;
             and for 3 months after last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current/recurrent diseases or relevant medical history.&#xD;
&#xD;
          -  Known exposure to investigational or marketed therapeutic proteins, such as monoclonal&#xD;
             antibodies, fusion proteins, bispecific molecules, or antibody drug conjugates, within&#xD;
             60 days or 5 half-lives (whichever is longer) prior to dosing.&#xD;
&#xD;
          -  Participants who have prior exposure to ALXN1830.&#xD;
&#xD;
          -  Current enrollment or past participation within the last 90 days before signing of&#xD;
             consent in this or any other interventional clinical study.&#xD;
&#xD;
          -  Participants with hepatitis B or C, or human immunodeficiency virus.&#xD;
&#xD;
          -  Participants who are either immunocompromised or have one of the following underlying&#xD;
             medical conditions: anatomic or functional asplenia (including sickle cell disease);&#xD;
             primary antibody deficiencies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALXN1830</keyword>
  <keyword>Autoimmune Disease</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

